Sodium Tanshinone IIA Sulfonate in Left Ventricular Remodeling Secondary to Acute Myocardial Infarction
Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Approximately 60 patients with ST-segment elevation myocardial infarction successfully
treated with primary percutaneous coronary intervention will be enrolled and randomized to
receive the sodium tanshinone IIA sulfonate in addition to standard therapy or the same
volume/day of normal saline.
The primary endpoint is the variation in LV end-diastolic volume index (LVEDVi) assessed with
cardiac magnetic resonance imaging (MRI) at baseline and 6 months.
Phase:
Phase 4
Details
Lead Sponsor:
Guangdong Provincial Hospital of Traditional Chinese Medicine